Top Industry Leaders in the Klinefelter Syndrome Treatment Market
Clarus Therapeutics Positive Phase III ROMEO-2 trial results demonstrating the long-term safety and efficacy of Jatenzo (testosterone undecanoate) in improving hypogonadism symptoms in Klinefelter Syndrome patients.
AndroGel (Mallinckrodt Pharmaceuticals) FDA approval for a generic version of Testosterone Gel 1.62%, offering a more affordable alternative for testosterone replacement therapy in Klinefelter Syndrome patients.
RegeneXbio Early-stage clinical trial initiated for RGX-314, a potential gene therapy candidate for treating the underlying cause of Klinefelter Syndrome.
Endocrinologics Collaboration with the University of California, San Diego to develop a new therapeutic agent for treating infertility in men with Klinefelter Syndrome.
List of Klinefelter Syndrome Treatment Key Companies in the Market
- Allergan plc
- AbbVie Inc.
- Endo Pharmaceuticals Inc.
- Kyowa Kirin International plc
- Eli Lilly and Company
- Mylan N.V.
- Lupin Pharmaceuticals
- Pfizer Inc